Brokerages Set Kenvue Inc. (NYSE:KVUE) Target Price at $19.50

Kenvue Inc. (NYSE:KVUE) has been assigned an average rating of “Hold” from the sixteen research firms that are presently covering the stock, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $19.3333.

A number of research analysts have recently commented on KVUE shares. Barclays reduced their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday. UBS Group lowered their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Wednesday, April 8th.

Kenvue Trading Up 1.1%

NYSE KVUE opened at $17.49 on Tuesday. The company’s fifty day simple moving average is $17.93 and its 200-day simple moving average is $17.08. Kenvue has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market cap of $33.57 billion, a P/E ratio of 22.71, a PEG ratio of 3.93 and a beta of 0.61.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $3.68 billion. During the same period in the previous year, the company posted $0.26 earnings per share. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. Equities research analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s payout ratio is presently 107.79%.

Institutional Trading of Kenvue

Institutional investors have recently added to or reduced their stakes in the business. Salomon & Ludwin LLC bought a new stake in Kenvue during the third quarter valued at $25,000. NBT Bank N A NY increased its stake in Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the last quarter. Cornerstone Planning Group LLC grew its position in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new position in shares of Kenvue during the fourth quarter worth about $26,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.